# China Structural Heart Devices Market > China Structural Heart Devices Market Research Report By Type (Heart Valve Devices, Annuloplasty Rings, Occluders, Delivery Systems), By Indication (Valvular Heart Disease, Cardiomyopathy) and By Procedure (Replacement Procedures, Repair Procedures) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.68% - **2024:** $ 57.75 Million - **2025:** $ 61.61 Million - **2035:** $ 117.66 Million - **Key Players:** Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), LivaNova (GB), Terumo Corporation (JP), Cardinal Health (US), AtriCure (US) **Report ID:** MRFR/HC/55143-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/china-structural-heart-devices-market-56909 --- ## Market Summary ## **China Structural Heart Devices Market Overview** As per MRFR analysis, the China Structural Heart Devices Market Size was estimated at 53.25 (USD Million) in 2024.The China Structural Heart Devices Market Industry is expected to grow from 57.75(USD Million) in 2025 to 144.83 (USD Million) by 2035. The China Structural Heart Devices Market CAGR (growth rate) is expected to be around 8.717% during the forecast period (2025 - 2035). **Key China Structural Heart Devices Market Trends Highlighted** China’s structural heart devices market is experiencing significant growth, driven by an aging population and a rising prevalence of cardiovascular diseases. The expansion of healthcare facilities and the increasing availability of advanced medical technology are key market drivers in the region. The Chinese government has been actively promoting initiatives to improve healthcare access and affordability, leading to enhanced investment in innovative heart care solutions.  Additionally, an increasing focus on non-invasive procedures has encouraged more hospitals to adopt modern structural heart devices, thereby facilitating better patient outcomes.Furthermore, opportunities exist in personalized medicine and targeted therapies as healthcare providers in China look to tailor treatments to individual patient needs. There is a rise in the interest among domestic manufacturers to develop and introduce cost-effective solutions, which could capture a significant share of the market. The growing collaboration between global companies and local firms can also result in faster distribution and greater access to novel technologies, optimizing patient care.  Recent trends indicate a shift toward minimally invasive procedures in response to changing patient preferences, which aligns with global standards in heart treatment.The rise in telemedicine and digital health solutions, particularly after the COVID-19 pandemic, is influencing patient management and follow-up care, highlighting the need for interconnected health systems. As healthcare reforms continue to unfold in China, staying attuned to these ongoing trends will be essential for stakeholders aiming to capitalize on the evolving structural heart devices market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **China Structural Heart Devices Market Drivers** **Aging Population in China** China is experiencing a significant demographic shift with a rapidly aging population. According to the National Bureau of Statistics of China, by the year 2035, approximately 28% of the Chinese population will be over the age of 60. This shift is predisposed to increasing cardiac conditions, necessitating the use of Structural Heart Devices. The growing elderly demographic leads to an uptick in cardiovascular diseases, compelling the healthcare sector to adopt innovative solutions for heart disease management. The Chinese Society of Cardiology and other leading organizations have been promoting the value of these devices for ample treatment, thus significantly propelling the China Structural Heart Devices Market Industry. The forecasts indicate that there is an emergent and fundamental need to procure advanced medical equipment for servicing the ever-increasing number of patients. This is gradually helping the market growth. **Government Initiatives and Healthcare Reforms** The Chinese government has launched various healthcare reforms to enhance medical services and accessibility, which greatly influences the Structural Heart Devices Market. With initiatives like 'Healthy China 2030,' the government aims to improve healthcare services and increase investment in advanced medical technology.  In 2020, the government allocated substantial funding to support cardiovascular disease prevention and intervention strategies. This funding boosts Research and Development efforts for Structural Heart Devices, enabling manufacturers to innovate and improve product offerings.The result is an anticipated surge in the availability and adoption of these devices in hospitals across the nation, reinforcing the position of the China Structural Heart Devices Market Industry. **Technological Advancements in Medical Devices** The rapid advancement in medical technology is another significant driver for the China Structural Heart Devices Market. Innovations such as minimally invasive procedures and enhanced imaging technologies are paving the way for better patient outcomes and quicker recovery times.  Reports from the National Medical Products Administration of China indicate a year-on-year increase in approvals for new cardiovascular devices, showcasing the growing investment in technology.Established companies like Medtronic and Boston Scientific are at the forefront of these technological improvements, continuously releasing innovative products. This progression in technology resonates with healthcare providers' preference for advanced devices, thereby fueling the growth of the China Structural Heart Devices Market Industry. **China Structural Heart Devices Market Segment Insights** **Structural Heart Devices Market Type Insights** The China Structural Heart Devices Market is characterized by a diverse range of types that cater to various cardiac conditions. Within this market, Heart Valve Devices stand out due to their essential role in treating valvular heart diseases, which are prevalent in China, given the country's growing aging population and rising incidence of cardiovascular diseases.  As healthcare awareness increases, these devices are being adopted more widely in clinical settings, driven by advancements in technology and minimally invasive procedures enhance patient outcomes. Annuloplasty Rings are another significant component of this market, primarily used in reconstructive heart surgery. Their importance lies in maintaining the shape of the heart valve and ensuring proper function, which directly impacts patient recovery and longevity. The demand for these devices aligns with China's evolving healthcare landscape, which increasingly prioritizes effective cardiac care solutions due to the burden of heart disease in the region. Occluders, designed to close off blood vessels or defects in the heart, have also gained traction as they provide less invasive alternatives to traditional surgical methods. The preference for these devices can be attributed to their ability to reduce recovery time and improve overall patient satisfaction, making them a crucial part of the market. Delivery Systems, essential for the effective deployment of various structural heart devices, underpin the efficiency and success of procedures related to these devices.  They ensure precise placement and minimize complications during the procedure, thereby fostering their adoption in hospitals across China. Altogether, the segments within the China Structural Heart Devices Market illustrate a robust and growing sector driven by innovation, increasing healthcare initiatives, and a rising focus on patient-centered care solutions that effectively address the challenges posed by cardiovascular diseases in the region. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Structural Heart Devices Market Indication Insights** The China Structural Heart Devices Market is witnessing significant growth, particularly in the Indication segment, which includes conditions such as Valvular Heart Disease and Cardiomyopathy. Valvular Heart Disease is becoming increasingly prevalent due to the aging population and rising incidence of rheumatic heart disease in China. This segment is crucial as it often requires surgical intervention, driving demand for advanced structural heart devices to improve patient outcomes.  Cardiomyopathy, on the other hand, represents a complex group of diseases affecting the heart muscle, leading to severe complications such as heart failure.The growing awareness and improved diagnostic capabilities continue to enhance the identification and treatment of these conditions, benefiting the overall market growth. Moreover, the Chinese government has been focusing on improving healthcare infrastructure and expanding access to innovative medical devices, further propelling advancements in the Structural Heart Devices Market. As the healthcare landscape evolves, the integration of cutting-edge technologies and personalized treatment strategies is expected to offer new opportunities for addressing the challenges posed by these serious heart conditions. **Structural Heart Devices Market Procedure Insights** The China Structural Heart Devices Market is experiencing substantial growth, particularly within the Procedure segment, which encompasses both Replacement and Repair Procedures. As the prevalence of cardiovascular diseases rises in China, driven by an aging population and urban lifestyle changes, there is an increasing demand for effective treatment options. Replacement Procedures, often involving valves and other cardiovascular structures, play a critical role in enhancing patients' quality of life, while Repair Procedures address structural defects to mitigate severe complications. Advances in technology and an expanding therapeutic landscape are fostering innovation within these procedures, leading to improved patient outcomes. Moreover, growing awareness among healthcare professionals and the government’s initiatives in expanding healthcare access are contributing positively to the market dynamics. The ongoing Research and Development efforts are crucial as they pave the way for the introduction of more sophisticated and minimally invasive techniques, making these procedures safer and more efficient. As regulatory conditions evolve, there is a notable potential for market expansion, which benefits both patients and healthcare systems through reduced procedural risks and overall costs. **China Structural Heart Devices Market Key Players and Competitive Insights** The China Structural Heart Devices Market is characterized by a dynamic competitive landscape driven by technological advancements, increasing prevalence of cardiovascular disorders, and growing investment in healthcare infrastructure. As a rapidly evolving segment within the broader medical devices industry, it has attracted various global and local manufacturers seeking to expand their presence in the region. The market is distinguished by strict regulatory requirements and an increasing emphasis on patient-centric solutions, which compel companies to innovate consistently. With healthcare spending on the rise and an aging population, the demand for advanced structural heart devices, including transcatheter heart valves, closure devices, and other interventional tools, is on the upswing, prompting competitors to strengthen their market positions and capitalize on the growth opportunities available. Medtronic has established a formidable presence in the China Structural Heart Devices Market, leveraging its extensive portfolio of innovative products and a robust distribution network. The company is recognized for its pioneering technology in transcatheter aortic valve replacement and septal occlusion devices, which have positioned it as a leader in addressing complex heart conditions. Medtronic's strengths in research and development enable it to introduce cutting-edge solutions tailored to the unique demands of the Chinese healthcare environment. Additionally, the company has prioritized partnerships with local healthcare providers and authorities, facilitating smoother market entry and expansion.  Such collaborations have significantly bolstered Medtronic's capabilities in serving patients across China, allowing it to maintain its competitive edge while enhancing brand recognition and trust among healthcare professionals.Terumo has made significant inroads into the China Structural Heart Devices Market through a focused strategy characterized by an extensive range of innovative cardiovascular products and a commitment to improving patient outcomes. The company's offerings include advanced closure devices, catheter systems, and products designed for minimally invasive procedures. Terumo's strengths lie in its commitment to quality and safety, reinforced by stringent manufacturing standards and clinical evidence supporting its product efficacy.  With a strong focus on research and development, Terumo has been actively engaged in collaborations and partnerships to enhance its market position, successfully navigating regulatory challenges. Furthermore, the company has strategically pursued mergers and acquisitions to broaden its technological capabilities and expand its market share in the region, ensuring its offerings resonate with the evolving needs of the Chinese healthcare system and securing its competitive stance in the structural heart devices sector. **Key Companies in the China Structural Heart Devices Market Include:** - Medtronic - Terumo - Neovasc - Aviir - Cypress Medical - Boston Scientific - Abbott - Biosense Webster - Zhuhai Hokai Medical Instruments - LivaNova - Micro Interventional Devices - Cardiac Rhythm Management - Janssen - Edwards Lifesciences - MitraClip **China Structural Heart Devices Market Industry Developments** The China Structural Heart Devices Market has witnessed significant developments and current affairs recently. In October 2023, Medtronic announced the expansion of its market offerings, focusing on innovative technologies for structural heart interventions in China. Boston Scientific has been enhancing its presence with new product approvals, catering to the growing demand for minimally invasive treatments.  Additionally, Terumo has been actively working on collaborations with local hospitals to advance research and development initiatives in the Chinese market. Notably, in August 2023, Edwards Lifesciences launched a new heart valve product tailored for Chinese patients, addressing the specific needs of the population. Regarding mergers and acquisitions, Neovasc has been in discussions for strategic partnerships aimed at expanding its reach in the region, reflecting the ongoing trend of consolidation in this market space.  Throughout 2022, the emphasis on cardiac rhythm management technologies has grown, driven by increasing cardiovascular diseases in China, which has significantly affected market valuations and investment strategies amongst players like Abbott and LivaNova. The robust growth trajectory of this market is also supported by favorable government policies encouraging medical innovations and improved healthcare access. **China Structural Heart Devices Market Segmentation Insights** **Structural Heart Devices Market Type Outlook** - Heart Valve Devices - Annuloplasty Rings - Occluders - Delivery Systems **Structural Heart Devices Market Indication Outlook** - Valvular Heart Disease - Cardiomyopathy **Structural Heart Devices Market Procedure Outlook** - Replacement Procedures - Repair Procedures ## Market Drivers ### Government Initiatives and Funding Government initiatives aimed at improving healthcare infrastructure and access to advanced medical technologies are pivotal for the structural heart-devices market. The Chinese government has been actively investing in healthcare reforms, which include increasing funding for cardiovascular health programs. These initiatives are designed to enhance the availability of structural heart devices in hospitals and clinics across the country. In recent years, the government has allocated significant resources to support research and development in the medical device sector, which is expected to bolster the market. By 2025, it is anticipated that government funding will contribute to a 15% increase in the adoption of structural heart devices, thereby expanding the market's reach and accessibility. ### Increase in Healthcare Expenditure The rise in healthcare expenditure in China is a significant driver for the structural heart-devices market. As the country continues to develop economically, there is a corresponding increase in spending on healthcare services and technologies. In 2025, healthcare expenditure is projected to reach approximately 7% of GDP, reflecting a growing commitment to improving health outcomes. This increase in funding allows for greater investment in advanced medical technologies, including structural heart devices. Hospitals and healthcare facilities are likely to allocate more resources towards acquiring these devices, thereby enhancing their treatment capabilities. Consequently, the structural heart-devices market is expected to experience robust growth as healthcare providers strive to meet the rising demand for effective cardiovascular treatments. ### Growing Awareness and Patient Education The rising awareness of heart health and the importance of early intervention is driving the structural heart-devices market in China. Educational campaigns and community outreach programs have been instrumental in informing the public about cardiovascular diseases and available treatment options. As patients become more informed, they are more likely to seek medical advice and treatment, leading to increased demand for structural heart devices. This trend is further supported by healthcare providers who are emphasizing the importance of preventive care and timely interventions. The structural heart-devices market is expected to benefit from this heightened awareness, as more patients opt for advanced treatment solutions to manage their heart conditions effectively. ### Rising Incidence of Cardiovascular Diseases The increasing prevalence of cardiovascular diseases in China is a primary driver for the structural heart-devices market. According to recent health statistics, cardiovascular diseases account for approximately 40% of all deaths in the country. This alarming trend necessitates advanced medical interventions, including structural heart devices, to manage and treat these conditions effectively. The demand for innovative solutions is further fueled by the growing awareness of heart health among the population. As healthcare providers seek to improve patient outcomes, investments in structural heart devices are likely to rise, indicating a robust growth trajectory for the market. Furthermore, the Chinese government has been promoting initiatives aimed at reducing the burden of cardiovascular diseases, which may lead to increased funding and support for the development and distribution of these devices. ### Technological Innovations in Medical Devices Technological advancements in medical devices are significantly influencing the structural heart-devices market. Innovations such as minimally invasive procedures, advanced imaging techniques, and improved materials are enhancing the efficacy and safety of heart devices. For instance, the introduction of transcatheter aortic valve replacement (TAVR) has revolutionized treatment options for patients with aortic stenosis. The market is projected to grow as manufacturers invest in research and development to create next-generation devices that offer better performance and patient outcomes. In 2025, the market for structural heart devices in China is expected to reach approximately $2 billion, driven by these technological innovations. As healthcare professionals increasingly adopt these advanced solutions, the structural heart-devices market is poised for substantial growth. ## Future Outlook The [Structural Heart Devices Market](https://www.marketresearchfuture.com/reports/structural-heart-devices-market-6385) in China is projected to grow at a 6.68% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of heart diseases, and rising healthcare expenditure. **New opportunities:** - Development of minimally invasive surgical techniques for heart valve repair. Expansion of telehealth services for remote patient monitoring and follow-up. Investment in R&D for innovative biomaterials in device manufacturing. By 2035, the structural heart-devices market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Transcatheter Aortic Valve Replacement (Largest) vs. Mitral Valve Repair Devices (Fastest-Growing) In the China structural heart-devices market, Transcatheter Aortic Valve Replacement (TAVR) currently holds the largest market share, driven by its high adoption rates and effectiveness in treating severe aortic stenosis. Mitral Valve Repair Devices, while trailing in overall market share, have shown significant interest and investment, indicating a vibrant growth potential within this segment. The growth trends in the China structural heart-devices market are largely propelled by an aging population, increasing prevalence of cardiovascular diseases, and advancements in technology. Mitral Valve Repair Devices are emerging rapidly due to the growing recognition of less invasive treatment options, while TAVR continues to dominate due to its established efficacy and procedural benefits, positioning it well against the backdrop of evolving regulatory landscapes. Transcatheter Aortic Valve Replacement (Dominant) vs. Mitral Valve Repair Devices (Emerging) Transcatheter Aortic Valve Replacement (TAVR) is characterized by its minimally invasive procedure that offers significant benefits for patients with aortic valve stenosis, leading to its dominant position in the market. This segment has benefitted from technological advancements and strong clinical support. On the other hand, Mitral Valve Repair Devices are considered an emerging technology, gaining traction as more healthcare providers seek alternatives to traditional surgical methods. They are particularly appealing due to reduced recovery times and better patient outcomes. As healthcare focus shifts toward personalized and less invasive solutions, both segments are expected to witness dynamic growth, with TAVR maintaining its lead and Mitral Valve Repair Devices rapidly catching up. ### By Procedure Type: Minimally Invasive (Largest) vs. Surgical (Fastest-Growing) In the China structural heart-devices market, the procedure type segmentation showcases a compelling distribution of market share among Minimally Invasive, Surgical, and Percutaneous techniques. Currently, Minimally Invasive stands as the largest segment, driven by the growing preference for effective yet less invasive treatment options. Surgical methods, while historically prominent, are increasingly challenged by advancements in percutaneous technologies, shifting the competitive landscape. Growth trends indicate that the Surgical segment is emerging as the fastest-growing category, attributable to technological innovations and increasing acceptance of hybrid surgical techniques. Factors such as an aging population and rising cardiovascular diseases further drive the demand for both minimally invasive and surgical solutions. The overall trend leans towards integrating innovative techniques that combine the benefits of both segments, enhancing patient outcomes and adoption rates. Minimally Invasive (Dominant) vs. Surgical (Emerging) The Minimally Invasive segment represents a dominant force in the China structural heart-devices market, characterized by its emphasis on reduced recovery times and lower complications. This approach aligns with patient preferences for procedures that minimize trauma while ensuring effective treatment for structural heart conditions. Innovations in device design and surgical techniques have significantly contributed to this segment's appeal. Conversely, the Surgical segment is emerging as a vital player due to ongoing advancements and increased procedural efficiencies. Surgical methods are becoming more integrated with minimally invasive practices, allowing for a blend of both methods to address complex heart conditions. As surgical approaches evolve, they cater to a broader range of patients, enhancing surgical outcomes and driving growth. ### By Indication: Aortic Stenosis (Largest) vs. Mitral Regurgitation (Fastest-Growing) In the China structural heart-devices market, the indication segment reveals that Aortic Stenosis holds the largest market share, significantly outpacing other indications. Mitral Regurgitation and Heart Failure follow, with Mitral Regurgitation being recognized for its impressive growth rate, fueled by advancing technologies and increasing patient awareness. Growth trends within this segment are largely driven by the rising prevalence of cardiovascular diseases and an aging population. Additionally, innovations in device technology and improved procedural outcomes have contributed to the expanding market for Mitral Regurgitation treatments. As awareness of heart-related issues grows, both segments are set to carve out larger portions of the market in the coming years, supported by healthcare initiatives and enhanced access to care. Aortic Stenosis (Dominant) vs. Mitral Regurgitation (Emerging) Aortic Stenosis remains the dominant indication within the China structural heart-devices market, characterized by its robust demand for transcatheter aortic valve replacement (TAVR) procedures. This segment sees extensive support from established clinical practices and a solid base of healthcare providers trained in managing the condition. Conversely, Mitral Regurgitation is an emerging segment gaining traction, driven by innovative solutions such as percutaneous mitral valve repair techniques, which are rapidly gaining acceptance. While Aortic Stenosis benefits from a well-entrenched position, Mitral Regurgitation offers significant growth potential as it addresses a broader range of patient needs and paves the way for more treatment options. ### By End User: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing) In the China structural heart-devices market, hospitals represent the largest segment, capturing a significant share due to their comprehensive services and advanced infrastructure. Ambulatory surgical centers, while smaller in share, are rapidly gaining traction as more patients prefer outpatient procedures that minimize hospital stays. Cardiology clinics, although vital, currently hold a smaller market share, focusing primarily on specialized treatments and follow-up care for patients with cardiovascular conditions. The growth trends indicate a robust expansion in ambulatory surgical centers driven by the increasing preference for minimally invasive procedures and shorter recovery times, appealing to both patients and healthcare providers. Hospitals are expected to maintain their dominance, but the growth of specialized cardiology clinics is noteworthy as they adapt to evolving healthcare needs, emphasizing patient-centric models and collaborative approaches to heart care. Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging) Hospitals dominate the market due to their capacity to provide a wide range of healthcare services, equipped with advanced technology and expert personnel specializing in structural heart procedures. The expansive networks of hospitals allow them to handle complex cases, making them the preferred destination for critical care. In contrast, ambulatory surgical centers are emerging rapidly, driven by patient demand for cost-effective and efficient care. These centers focus on outpatient surgical procedures and have significantly lower operational costs, which translates into savings for patients. Their growth reflects a shift towards more accessible healthcare options, enhancing patient satisfaction through quicker recovery times and personalized care. ## Competitive Benchmarking The structural heart-devices market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of cardiovascular diseases. Key players such as Edwards Lifesciences (US), Medtronic (US), and Abbott Laboratories (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Edwards Lifesciences (US) focuses on innovation, particularly in transcatheter heart valves, while Medtronic (US) emphasizes a broad portfolio that includes both surgical and minimally invasive solutions. Abbott Laboratories (US) is leveraging its strong R&D capabilities to introduce novel devices, thereby positioning itself as a leader in the market. Collectively, these strategies foster a competitive environment that is increasingly centered on innovation and technological differentiation.In terms of business tactics, companies are localizing manufacturing to reduce costs and enhance supply chain efficiency. This approach is particularly relevant in China, where regulatory frameworks and market demands necessitate a tailored approach. The market structure appears moderately fragmented, with several players vying for market share, yet dominated by a few key companies that exert considerable influence over pricing and product development. The collective actions of these major players shape the competitive dynamics, as they strive to capture a larger share of the growing market. In October Medtronic (US) announced the launch of its latest transcatheter aortic valve replacement (TAVR) device, which is designed to improve patient outcomes through enhanced delivery systems. This strategic move underscores Medtronic's commitment to innovation and its focus on addressing the needs of patients with aortic stenosis. The introduction of this device is likely to strengthen Medtronic's position in the market, as it aligns with the increasing demand for less invasive treatment options. In September Abbott Laboratories (US) expanded its partnership with a leading Chinese hospital network to enhance clinical trials for its heart valve products. This collaboration is significant as it not only accelerates the development of new technologies but also facilitates Abbott's entry into the rapidly growing Chinese market. By aligning with local healthcare providers, Abbott is poised to gain valuable insights into patient needs and preferences, which could inform future product development. In November Edwards Lifesciences (US) announced a strategic investment in a local Chinese startup focused on artificial intelligence (AI) applications in cardiac care. This investment reflects a broader trend towards digitalization within the industry, as companies seek to integrate AI to improve diagnostic accuracy and patient management. Such initiatives are likely to enhance Edwards Lifesciences' competitive edge by positioning it at the intersection of technology and healthcare. As of November the competitive landscape is increasingly defined by trends such as digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and expanding market reach. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards a focus on technological innovation, reliability in supply chains, and enhanced patient outcomes. This transition may redefine how companies position themselves in the market, emphasizing the importance of adaptability and forward-thinking strategies. ## Recent News & Developments The China Structural Heart Devices Market has witnessed significant developments and current affairs recently. In October 2023, Medtronic announced the expansion of its market offerings, focusing on innovative technologies for structural heart interventions in China. Boston Scientific has been enhancing its presence with new product approvals, catering to the growing demand for minimally invasive treatments.  Additionally, Terumo has been actively working on collaborations with local hospitals to advance research and development initiatives in the Chinese market. Notably, in August 2023, Edwards Lifesciences launched a new heart valve product tailored for Chinese patients, addressing the specific needs of the population. Regarding mergers and acquisitions, Neovasc has been in discussions for strategic partnerships aimed at expanding its reach in the region, reflecting the ongoing trend of consolidation in this market space.  Throughout 2022, the emphasis on cardiac rhythm management technologies has grown, driven by increasing cardiovascular diseases in China, which has significantly affected market valuations and investment strategies amongst players like Abbott and LivaNova. The robust growth trajectory of this market is also supported by favorable government policies encouraging medical innovations and improved healthcare access. ## Report Scope | MARKET SIZE 2024 | 57.75(USD Million) | | --- | --- | | MARKET SIZE 2025 | 61.61(USD Million) | | MARKET SIZE 2035 | 117.66(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.68% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), LivaNova (GB), Terumo Corporation (JP), Cardinal Health (US), AtriCure (US) | | Segments Covered | Type, Procedure Type, Indication, End User | | Key Market Opportunities | Advancements in minimally invasive procedures enhance growth potential in the structural heart-devices market. | | Key Market Dynamics | Rising demand for minimally invasive procedures drives innovation in structural heart-devices within the competitive landscape. | | Countries Covered | China | ## Frequently Asked Questions **Q: What is the current valuation of the China structural heart-devices market?** A: The market valuation was $57.75 Million in 2024. **Q: What is the projected market size for the China structural heart-devices market by 2035?** A: The market is projected to reach $117.66 Million by 2035. **Q: What is the expected CAGR for the China structural heart-devices market during the forecast period 2025 - 2035?** A: The expected CAGR is 6.68% during the forecast period. **Q: Which companies are the key players in the China structural heart-devices market?** A: Key players include Edwards Lifesciences, Medtronic, Abbott Laboratories, Boston Scientific, LivaNova, Terumo Corporation, Cardinal Health, and AtriCure. **Q: What are the main segments of the China structural heart-devices market?** A: The main segments include Type, Procedure Type, Indication, and End User. **Q: What was the valuation of Transcatheter Aortic Valve Replacement in 2024?** A: The valuation for Transcatheter Aortic Valve Replacement was between $20.0 Million and $40.0 Million. **Q: How much is the Mitral Valve Repair Devices segment valued at in 2024?** A: The Mitral Valve Repair Devices segment was valued between $15.0 Million and $30.0 Million. **Q: What is the projected valuation for the Left Atrial Appendage Closure Devices segment by 2035?** A: The Left Atrial Appendage Closure Devices segment is expected to grow to between $10.0 Million and $20.0 Million by 2035. **Q: Which end user segment had the highest valuation in 2024?** A: The Hospitals segment had the highest valuation, ranging from $30.0 Million to $60.0 Million. **Q: What is the projected growth for the Pulmonary Valve Stenosis indication by 2035?** A: The Pulmonary Valve Stenosis indication is projected to grow to between $10.75 Million and $22.66 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-structural-heart-devices-market-56909*